This study is testing a new medicine called CMTX-101. CMTX-101 is a type of medicine called a monoclonal antibody, which helps fight bacterial infections by breaking down protective layers called biofilms that bacteria form. This study has two parts. The first part will test the medicine on healthy adults, and the second part will test it on patients with a lung infection called community-acquired bacterial pneumonia (CABP). The main goals are to see if the medicine is safe, how it behaves in the body, and if it causes the body to make antibodies against it.
- Study Length: Participants will receive one dose of CMTX-101 through an intravenous infusion, which takes 60 minutes.
- Eligibility: Participants must be 18 or older, and females must use birth control during the study.
- Risks: Those with certain medical conditions, like autoimmune diseases, or those who are pregnant, cannot participate.
You may be compensated for your time. Please consider the eligibility criteria and potential risks before deciding to participate, and consult with the study team for more details.
How understandable was the trial content above?
Hard to understand
Easy to understand